Therapeutics News and Research

RSS

Rhythm Pharmaceuticals completes $21M Series A equity financing

Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

Promising preliminary results from ProFibrix' Phase II trial of hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.

11 Mar 2010

PBI and TDI announce strategic licensing and collaborative research and development agreement

Pressure BioSciences, Inc. and Target Discovery, Inc.,, today announced a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement. Under the terms of the Agreement, PBI has been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis.

11 Mar 2010

Chelsea Therapeutics announces financial results for fourth quarter 2009

Chelsea Therapeutics International, Ltd. reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.

11 Mar 2010

Therapeutics News and Research

Rhythm Pharmaceuticals completes $21M Series A equity financing

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Cytori Therapeutics reports total revenues of $14.7M for 2009

Development of promising new cancer therapies: OICR announces $1M investment

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

OXiGENE signs definitive agreement to sell Common Stock

FDA provides guidance on Restanza clinical program in treatment of CABP

TTI granted exclusive worldwide rights to commercialize two immunology programs

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

Promising preliminary results from ProFibrix' Phase II trial of hemostat Fibrocaps

PBI and TDI announce strategic licensing and collaborative research and development agreement

Chelsea Therapeutics announces financial results for fourth quarter 2009

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News